Form 4: Artivion SVP Exercises Options, Sells Shares

Artivion's SVP of Clinical & MD Affairs, Marshall S. Stanton, exercised stock options and subsequently sold 18,200 shares of common stock for a significant profit.

Summary

• Marshall S. Stanton, SVP, Clinical & MD Affair at Artivion, Inc. (AORT), executed a pre-planned transaction under a Rule 10b5-1 plan.
• On August 27, 2025, Stanton acquired 18,200 shares of common stock by exercising stock options at a price of $11.03 per share.
• Immediately following the option exercise, he sold all 18,200 acquired shares of common stock at a weighted average price of $44.023 per share, with individual sale prices ranging from $43.84 to $44.26.
• After these transactions, Stanton's direct beneficial ownership of Artivion common stock decreased from 82,400 shares to 64,200 shares.
• The exercised stock options had a first exercisable date of November 8, 2023, and an expiration date of November 8, 2029, with vesting occurring at 33 1/3% per year from the grant date.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the officer realized a significant profit from a pre-planned transaction, the reduction in insider ownership can sometimes be viewed with slight caution by the market, even if it's for diversification or personal financial planning.

Positives

• The officer realized a substantial profit from the sale, indicating a significant increase in the company's stock value since the options were granted (sale price $44.023 vs. exercise price $11.03).
• The transaction was conducted under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not based on immediate, non-public information, which can mitigate concerns about insider selling.

Negatives

• An insider selling a significant number of shares, even if pre-planned, can sometimes be interpreted by the market as a signal of limited upside potential or a lack of confidence in the company's near-term growth prospects.
• The officer's direct beneficial ownership of common stock decreased by 18,200 shares, reducing their direct equity stake in the company.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This filing details an individual insider's transaction and does not provide broader industry context. Insider transactions are a common occurrence across all industries.

Related Party Transactions

• The transaction involves an officer of Artivion, Inc. exercising stock options and selling company shares, which is a related party transaction.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, potentially leading to short-term price fluctuations, although the pre-planned nature (10b5-1) mitigates some of the negative signaling.

Key Dates

Recommendation

While the insider sale might introduce a slight negative sentiment, the transaction was pre-planned under a 10b5-1 plan, which often indicates a non-discretionary sale for personal financial management rather than a reaction to new, negative information. The officer still retains a significant number of shares (64,200). Without additional information on the company's performance or strategic outlook, a 'hold' recommendation is appropriate, advising investors to monitor future company developments and broader market trends rather than reacting solely to this insider transaction.

Keywords

Artivion, AORT, Marshall S. Stanton, insider transaction, stock option exercise, share sale, Rule 10b5-1, officer transaction, common stock